IL-17 and Th17 cells in human inflammatory diseases

Microbes and Infection

Volumn 11, Issue 5, 2009, Pages 625-630

  Miossec, Pierre ^a  

^a University of Lyon   (France)

Author keywords

Cytokines; Destruction; IL 1; IL 17; Inflammation; TNF

Indexed keywords

ANTIINFLAMMATORY AGENT; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17 INHIBITOR; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17F; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY P40; OSTEOCLAST DIFFERENTIATION FACTOR; STAT3 PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG TARGETING; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; IMMUNOREGULATION; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PSORIASIS; RHEUMATOID ARTHRITIS; TH17 CELL; TH2 CELL; ULCERATIVE COLITIS;

ANIMALS; HUMANS; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-17; MICE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67349234068     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2009.04.003     Document Type: Article

References (58)

1. Miossec P. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum 48 (2003) 594-601
2. Fossiez F., Djossou O., Chomarat P., Flores-Romo L., Ait-Yahia S., Maat C., Pin J.J., Garrone P., Garcia E., Saeland S., Blanchard D., Gaillard C., Das Mahapatra B., Rouvier E., Golstein P., Banchereau J., and Lebecque S. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 183 (1996) 2593-2603
3. Yao Z., Painter S.L., Fanslow W.C., Ulrich D., Macduff B.M., Spriggs M.K., and Armitage R.J. Human IL-17: a novel cytokine derived from T cells. J Immunol 155 (1995) 5483-5486
4. Zrioual S., Toh M.L., Tournadre A., Zhou Y., Cazalis M.A., Pachot A., Miossec V., and Miossec P. IL-17RA and IL-17RC receptors are essential for IL-17A-induced ELR + CXC chemokine expression in synoviocytes and are overexpressed in rheumatoid blood. J Immunol 180 (2008) 655-663
5. Liang S.C., Tan X.Y., Luxenberg D.P., Karim R., Dunussi-Joannopoulos K., Collins M., and Fouser L.A. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203 (2006) 2271-2279
6. Zheng Y., Danilenko D.M., Valdez P., Kasman I., Eastham-Anderson J., Wu J., and Ouyang W. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445 (2007) 648-651
7. Yao Z., Fanslow W.C., Seldin M.F., Rousseau A.M., Painter S.L., Comeau M.R., Cohen J.I., and Spriggs M.K. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 3 (1995) 811-821
8. Yao Z., Spriggs M.K., Derry J.M., Strockbine L., Park L.S., VandenBos T., Zappone J.D., Painter S.L., and Armitage R.J. Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 9 (1997) 794-800
9. Toy D., Kugler D., Wolfson M., Bos T.V., Gurgel J., Derry J., Tocker J., and Peschon J. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 177 (2006) 36-39
10. Harrington L.E., Mangan P.R., and Weaver C.T. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 18 (2006) 349-356
11. Miossec P. Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified. Arthritis Rheum 56 (2007) 2111-2115
12. Iwakura Y., and Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 116 (2006) 1218-1222
13. Weaver C.T., Harrington L.E., Mangan P.R., Gavrieli M., and Murphy K.M. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24 (2006) 677-688
14. Bettelli E., Korn T., Oukka M., and Kuchroo V.K. Induction and effector functions of T(H)17 cells. Nature 453 (2008) 1051-1057
15. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., Lucian L., To W., Kwan S., Churakova T., Zurawski S., Wiekowski M., Lira S.A., Gorman D., Kastelein R.A., and Sedgwick J.D. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421 (2003) 744-748
16. Luger D., Silver P.B., Tang J., Cua D., Chen Z., Iwakura Y., Bowman E.P., Sgambellone N.M., Chan C.C., and Caspi R.R. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 205 (2008) 799-810
17. Kroenke M.A., Carlson T.J., Andjelkovic A.V., and Segal B.M. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med 205 (2008) 1535-1541
18. Aarvak T., Chabaud M., Miossec P., and Natvig J.B. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 162 (1999) 1246-1251
19. Page G., Sattler A., Kersten S., Thiel A., Radbruch A., and Miossec P. Plasma cell-like morphology of Th1-cytokine-producing cells associated with the loss of CD3 expression. Am J Pathol 164 (2004) 409-417
20. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 423 (2003) 356-361
21. Koenders M.I., Joosten L.A., and van den Berg W.B. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis 65 Suppl. 3 (2006) iii29-iii33
22. Chabaud M., Lubberts E., Joosten L., van Den Berg W., and Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 3 (2001) 168-177
23. Lubberts E., Joosten L.A., van de Loo F.A., Schwarzenberger P., Kolls J., and van den Berg W.B. Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm Res 51 (2002) 102-104
24. Lubberts E., Joosten L.A., Chabaud M., van Den Bersselaar L., Oppers B., Coenen-De Roo C.J., Richards C.D., Miossec P., and van Den Berg W.B. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 105 (2000) 1697-1710
25. Chabaud M., Durand J.M., Buchs N., Fossiez F., Page G., Frappart L., and Miossec P. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 42 (1999) 963-970
26. Sato K., Suematsu A., Okamoto K., Yamaguchi A., Morishita Y., Kadono Y., Tanaka S., Kodama T., Akira S., Iwakura Y., Cua D.J., and Takayanagi H. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203 (2006) 2673-2682
27. Page G., and Miossec P. RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes. Arthritis Rheum 52 (2005) 2307-2312
28. Andersson M.K., Lundberg P., Ohlin A., Perry M.J., Lie A., Stark A., and Lerner U.H. Effects on osteoclast and osteoblast activities in cultured mouse calvarial bones by synovial fluids from patients with a loose joint prosthesis and from osteoarthritis patients. Arthritis Res Ther 9 (2007) R18
29. Oda T., Yoshie H., and Yamazaki K. Porphyromonas gingivalis antigen preferentially stimulates T cells to express IL-17 but not receptor activator of NF-kappaB ligand in vitro. Oral Microbiol Immunol 18 (2003) 30-36
30. Kirkham B.W., Lassere M.N., Edmonds J.P., Juhasz K.M., Bird P.A., Lee C.S., Shnier R., and Portek I.J. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 54 (2006) 1122-1131
31. Koenders M.I., Lubberts E., van de Loo F.A., Oppers-Walgreen B., van den Bersselaar L., Helsen M.M., Kolls J.K., Di Padova F.E., Joosten L.A., and van den Berg W.B. Interleukin-17 acts independently of TNF-alpha under arthritic conditions. J Immunol 176 (2006) 6262-6269
32. Zaba L.C., Cardinale I., Gilleaudeau P., Sullivan-Whalen M., Farinas M.S., Fuentes-Duculan J., Novitskaya I., Khatcherian A., Bluth M.J., Lowes M.A., and Krueger J.G. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med (2007)
33. Yagi Y., Andoh A., Inatomi O., Tsujikawa T., and Fujiyama Y. Inflammatory responses induced by interleukin-17 family members in human colonic subepithelial myofibroblasts. J Gastroenterol 42 (2007) 746-753
34. Kobayashi T., Okamoto S., Hisamatsu T., Kamada N., Chinen H., Saito R., Kitazume M.T., Nakazawa A., Sugita A., Koganei K., Isobe K.I., and Hibi T. IL-23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut (2008)
35. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3 (2003) 133-146
36. Constantinescu C.S., Wysocka M., Hilliard B., Ventura E.S., Lavi E., Trinchieri G., and Rostami A. Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis. J Immunol 161 (1998) 5097-5104
37. Yago T., Nanke Y., Kawamoto M., Furuya T., Kobashigawa T., Kamatani N., and Kotake S. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther 9 (2007) R96
38. Chen Y., Langrish C.L., McKenzie B., Joyce-Shaikh B., Stumhofer J.S., McClanahan T., Blumenschein W., Churakovsa T., Low J., Presta L., Hunter C.A., Kastelein R.A., and Cua D.J. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 116 (2006) 1317-1326
39. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., Klonowski P., Austin A., Lad N., Kaminski N., Galli S.J., Oksenberg J.R., Raine C.S., Heller R., and Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8 (2002) 500-508
40. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., Giuliani F., Arbour N., Becher B., and Prat A. Human T(H)17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med (2007)
41. Minegishi Y., Saito M., Tsuchiya S., Tsuge I., Takada H., Hara T., Kawamura N., Ariga T., Pasic S., Stojkovic O., Metin A., and Karasuyama H. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448 (2007) 1058-1062
42. Ma C.S., Chew G.Y., Simpson N., Priyadarshi A., Wong M., Grimbacher B., Fulcher D.A., Tangye S.G., and Cook M.C. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med 205 (2008) 1551-1557
43. Dong C. IL-23/IL-17 biology and therapeutic considerations. J Immunotoxicol 5 (2008) 43-46
44. Koenders M.I., Lubberts E., Oppers-Walgreen B., van den Bersselaar L., Helsen M.M., Di Padova F.E., Boots A.M., Gram H., Joosten L.A., and van den Berg W.B. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 167 (2005) 141-149
45. Chabaud M., and Miossec P. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum 44 (2001) 1293-1303
46. Ivanov II B.S., McKenzie, Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., Cua D.J., and Littman D.R. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17 + T helper cells. Cell 126 (2006) 1121-1133
47. Krueger G.G., Langley R.G., Leonardi C., Yeilding N., Guzzo C., Wang Y., Dooley L.T., and Lebwohl M. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356 (2007) 580-592
48. Mannon P.J., Fuss I.J., Mayer L., Elson C.O., Sandborn W.J., Present D., Dolin B., Goodman N., Groden C., Hornung R.L., Quezado M., Yang Z., Neurath M.F., Salfeld J., Veldman G.M., Schwertschlag U., and Strober W. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 351 (2004) 2069-2079
49. Fuss I.J., Becker C., Yang Z., Groden C., Hornung R.L., Heller F., Neurath M.F., Strober W., and Mannon P.J. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis 12 (2006) 9-15
50. Sarkar S., Tesmer L.A., Hindnavis V., Endres J.L., and Fox D.A. Interleukin-17 as a molecular target in immune-mediated arthritis: immunoregulatory properties of genetically modified murine dendritic cells that secrete interleukin-4. Arthritis Rheum 56 (2006) 89-100
51. Kleinschek M.A., Owyang A.M., Joyce-Shaikh B., Langrish C.L., Chen Y., Gorman D.M., Blumenschein W.M., McClanahan T., Brombacher F., Hurst S.D., Kastelein R.A., and Cua D.J. IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med 204 (2007) 161-170
52. Owyang A.M., Zaph C., Wilson E.H., Guild K.J., McClanahan T., Miller H.R., Cua D.J., Goldschmidt M., Hunter C.A., Kastelein R.A., and Artis D. Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. J Exp Med 203 (2006) 843-849
53. Bettelli E., Oukka M., and Kuchroo V.K. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 8 (2007) 345-350
54. Nadkarni S., Mauri C., and Ehrenstein M.R. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 204 (2007) 33-39
55. Dinarello C.A. Blocking IL-1 in systemic inflammation. J Exp Med 201 (2005) 1355-1359
56. Yokota S., Miyamae T., Imagawa T., Iwata N., Katakura S., Mori M., Woo P., Nishimoto N., Yoshizaki K., and Kishimoto T. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 52 (2005) 818-825
57. Dubin P.J., and Kolls J.K. IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol (2006)
58. + T cells mediate abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism. J Immunol 170 (2003) 1958-1963